Loading...

Matthew Cooperberg, MD

TitleAssociate Professor
SchoolUCSF School of Medicine
DepartmentUrology
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7171
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Yale UniversityM.D.2000School of Medicine

    Collapse Overview 
    Collapse overview
    Health Services

    Both clinician and patient decisions influence the choices about the type of treatment a patient will receive for localized prostate and kidney (renal) cancer. Matthew Cooperberg, MD, MPH is conducting an ongoing research program to study national prostate cancer management trends, based on data from CaPSURE and other sources. His analyses have looked at changes in cancer risk over time, testing and treatment for prostate cancer, local variation in treatment, and the impact of socio-demographic factors on type of treatment and outcomes. Through the creation of a San Francisco General Hospital (SFGH) prostate cancer patient registry, preliminary analysis show that low socioeconomic status patients are treated for a higher percentage of high-risk disease than patients with a higher socioeconomic status. Using data from CaPSURE, the NCDB, SFGH and in collaboration with the Urologic Diseases in America project he continues to explore these topic in depth.


    Prostate Cancer Risk Assessment and Comparative Effectiveness Research

    Properly treating prostate cancer requires determining how likely is it that the cancer will progress. Cooperberg led the team that developed the UCSF-CAPRA score, a prostate cancer risk assessment tool that has been validated in several multi-institutional studies in the U.S. and Europe. CAPRA predicts biochemical recurrence-free survival (PSA level does not rise) after radical prostatectomy with an accuracy at least as good as more mathematically complex nomograms that require complex tables or computer software to calculate and other risk assessment instruments. The score is easy to calculate, and can be used to predict an individual's likelihood of metastasis, cancer-specific mortality, and overall mortality after treatment by surgery, radiation therapy, or androgen deprivation therapy.

    Cooperberg is currently developing a post-operative extension of the CAPRA score (CAPRA-S). After surgery additional information is available from the pathologist's analysis of the removed prostate. This information can help identify men who will benefit from additional therapy such as radiation and/or hormonal therapy after surgery. CAPRA-S will help in that decision making process. Cooperberg is also collaborating with a group of Japanese scientist to develop a prediction instrument specifically applicable to high-risk patients and patients receiving androgen deprivation therapy (J-CAPRA). As new biomarkers, such as genomic and advanced imaging data, are proven valid by UCSF Urology and collaborating laboratory investigators, Cooperberg plans to integrate the information into the current standard measures of risk and outcomes to improve risk assessment. These findings will help men determine with greater confidence whether active surveillance, surgery, radiation, hormonal therapy, or some combination may be most appropriate for them.

    Because accurate risk assessment is essential to compare the effectiveness of different prostate cancer treatments, Cooperberg is currently conducting such comparison studies using CaPSURE data. These data will provide a unique source of insight for future comparative effectiveness research.


    Survivorship

    Cooperberg is collaborating on a project that will lead to better clinical care for cancer survivors. His efforts have helped to develop UCSF’s Urologic Oncology Database (UODB) into a comprehensive data repository for clinical information about patients treated for prostate, bladder, and renal cancers. With the Urology Department’s information experts Cooperberg is developing an automated process to further augment UODB by automatically transferring data from the UCSF Medical Center’s information system into UODB. In collaboration with UCSF Breast Oncology and a health care web services company Cooperberg is developing an electronic survey for cancer patients. Patients will complete a health history and health-related quality of life (HRQOL) survey prior to their first visit to the clinic and at defined intervals after treatment. This effort is expected to help patients and clinicians track HRQOL outcomes, such as urinary and sexual function, after treatment. The survey will help physicians to identify those patients who may need to be seen in clinic more or less frequently.


    Small Renal Masses

    In collaboration with the laboratory of John Kurhanewicz, PhD, Cooperberg is conducting a study to see if magnetic resonance spectroscopy (MRS) can be used to non-invasively diagnosis small renal tumors. MRS is a specialized technique associated with magnetic resonance imaging (MRI). MRS equipment can be used to pick up signals from different chemical nuclei within the body. A preliminary laboratory study is using tissue to identify the specific MRS signals associated with a variety of renal tumors. Once renal tumor signals have been identified, Cooperberg plans to test the ability of MRS to accurately analyze renal tumors in patients. This will be done by using MRS imaging technology on patients who are already scheduled for renal cancer surgery prior to their operation. The pre and post surgery information can be analyzed to determine if the information collected non-invasively by the MRS technology matches the histology and grade of the actual tumor.


    Collapse Research 
    Collapse Research Activities and Funding
    Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment
    NIH/NCI R01CA198145Aug 10, 2016 - Jul 31, 2021
    Role: Principal Investigator
    Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment
    NIH/NCI R01CA198145Aug 10, 2016 - Jul 31, 2021
    Role: Principal Investigator
    Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment
    NIH/NCI R01CA198145Aug 10, 2016 - Jul 31, 2021
    Role: Principal Investigator
    Prospective validation of a multi-marker prostate cancer prediction model
    NIH/NCI R01CA160816Aug 8, 2012 - May 31, 2016
    Role: Co-Principal Investigator
    Prospective validation of a multi-marker prostate cancer prediction model
    NIH/NCI R01CA160816Aug 8, 2012 - May 31, 2016
    Role: Co-Principal Investigator
    Prospective validation of a multi-marker prostate cancer prediction model
    NIH/NCI R01CA160816Aug 8, 2012 - May 31, 2016
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Selected Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2016 Dec 27. PMID: 28026865.
      View in: PubMed
    2. Lavery HJ, Cooperberg MR. Clinically localized prostate cancer in 2017: A review of comparative effectiveness. Urol Oncol. 2016 Dec 17. PMID: 27998677.
      View in: PubMed
    3. Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. Eur Urol. 2016 Dec 08. PMID: 27940155.
      View in: PubMed
    4. Emami NC, Leong L, Wan E, Van Blarigan EL, Cooperberg M, Tenggara I, Carroll PR, Chan JM, Witte JS, Simko JP. Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate. 2016 Nov 30. PMID: 27900799.
      View in: PubMed
    5. Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol. 2016 Nov 23. PMID: 27889277.
      View in: PubMed
    6. Cooperberg MR. Magnetic Resonance Imaging-targeted Prostate Biopsies: Is the Right Technique the Right Question? Eur Urol. 2016 Nov 10. PMID: 27839778.
      View in: PubMed
    7. Cooperberg MR. Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. Eur Urol. 2016 Nov 3. PMID: 27817968.
      View in: PubMed
    8. Tyson MD, Alvarez J, Koyama T, Hoffman KE, Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen VW, Penson DF, Barocas DA. Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. Eur Urol. 2016 Nov 2. PMID: 27816300.
      View in: PubMed
    9. Cooperberg MR. What Early ProtecT Results Have Confirmed About Risk-stratified Prostate Cancer Management. Eur Urol. 2016 Nov 1. PMID: 27815085.
      View in: PubMed
    10. McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol. 2016 Nov; 40(11):1439-1456. PMID: 27635949.
      View in: PubMed
    11. Cooperberg MR. Active Surveillance for Low-Risk Prostate Cancer-An Evolving International Standard of Care. JAMA Oncol. 2016 Oct 20. PMID: 27768167.
      View in: PubMed
    12. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620. PMID: 27743920.
      View in: PubMed
    13. Wadhwa H, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. Prostate Cancer Prostatic Dis. 2016 Dec; 19(4):423-428. PMID: 27698440.
      View in: PubMed
    14. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg M, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 Sep 29. PMID: 27688020.
      View in: PubMed
    15. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate. 2017 Feb; 77(2):154-163. PMID: 27683213.
      View in: PubMed
    16. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clin Genitourin Cancer. 2016 Aug 31. PMID: 27692812.
      View in: PubMed
    17. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg M, Greene KL, et al. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Jul 25. PMID: 27453303.
      View in: PubMed
    18. Leapman MS, Ameli N, Shinohara K, Nguyen HG, Meng MV, Cooperberg M, Carroll PR, et al. Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clin Genitourin Cancer. 2016 Jul 21. PMID: 27522449.
      View in: PubMed
    19. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM, Carroll P, Eastham J, Gomella L, Klein EA. An Approach Using PSA Levels of 1.5?ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016 Oct; 96:116-120. PMID: 27450937.
      View in: PubMed
    20. Cooperberg MR. Prostate cancer: Why the prostate arm of the PLCO trial failed and what it has taught us. Nat Rev Urol. 2016 Aug; 13(8):439-40. PMID: 27400667.
      View in: PubMed
    21. Suskind AM, Jin C, Cooperberg MR, Finlayson E, Boscardin WJ, Sen S, Walter LC. Preoperative Frailty Is Associated With Discharge to Skilled or Assisted Living Facilities After Urologic Procedures of Varying Complexity. Urology. 2016 Nov; 97:25-32. PMID: 27392651.
      View in: PubMed
    22. Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis. 2016 Dec; 19(4):380-384. PMID: 27377207.
      View in: PubMed
    23. Roth JA, Gulati R, Gore JL, Cooperberg M, Etzioni R. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol. 2016 Jul 1; 2(7):890-8. PMID: 27010943.
      View in: PubMed
    24. Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 Nov; 196(5):1408-1414. PMID: 27352635.
      View in: PubMed
    25. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology. 2016 Oct; 96:171-176. PMID: 27318265.
      View in: PubMed
    26. Leapman MS, Nguyen HG, Cooperberg MR. Clinical Utility of Biomarkers in Localized Prostate Cancer. Curr Oncol Rep. 2016 May; 18(5):30. PMID: 27023445.
      View in: PubMed
    27. Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, Hakim L, Chiong E, Letran J, Umbas R, Suzuki K, Nishimura K, Ong TA, Lojanapiwat B, Wu TL, Kim WJ, Murphy D, Ogawa O, Carroll P, Naito S, Tsukamoto T. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate Int. 2016 Sep; 4(3):88-96. PMID: 27689065.
      View in: PubMed
    28. Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LL, Tenggara I, Chadwich K, Van Der Kwast T, Fleshner N, Davicioni E, Carroll PR, Cooperberg MR, Chan JM, Simko JP. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. J Mol Diagn. 2016 May; 18(3):395-406. PMID: 26945428.
      View in: PubMed
    29. Cooperberg M. When to Start Prostate Cancer Screening and When to Stop: Insights from Göteborg. J Urol. 2016 May; 195(5):1325-6. PMID: 26901508.
      View in: PubMed
    30. Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, Morgan SC, Tyldesley S, Haluschak JJ, Tan W, Justman S, Jain S. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016 Jun 20; 34(18):2182-90. PMID: 26884580.
      View in: PubMed
    31. Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU Int. 2016 Oct; 118(4):570-7. PMID: 26762961.
      View in: PubMed
    32. Tasian GE, Cooperberg MR. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. Eur Urol. 2016 Feb; 69(2):374-5. PMID: 26758522.
      View in: PubMed
    33. Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):547-54. PMID: 26809276.
      View in: PubMed
    34. Cary C, Odisho AY, Cooperberg MR. Variation in prostate cancer treatment associated with population density of the county of residence. Prostate Cancer Prostatic Dis. 2016 Jun; 19(2):174-9. PMID: 26782713.
      View in: PubMed
    35. Suskind AM, Walter LC, Jin C, Boscardin J, Sen S, Cooperberg MR, Finlayson E. Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database. BJU Int. 2016 May; 117(5):836-42. PMID: 26691588.
      View in: PubMed
    36. Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology. 2016 Mar; 89:69-75. PMID: 26723180.
      View in: PubMed
    37. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2016 Mar; 23(3):241-6. PMID: 26667212.
      View in: PubMed
    38. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 2016 Jan 15; 122(2):222-9. PMID: 26484853.
      View in: PubMed
    39. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K, Murphy DG, Penson DF, Miller DC. Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. Eur Urol 2016;69:1013-4. Eur Urol. 2016 Jun; 69(6):1015. PMID: 26443428.
      View in: PubMed
    40. Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg M, Freedland SJ, Vidal AC. Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int. 2016 Aug; 118(2):250-7. PMID: 26351095.
      View in: PubMed
    41. O'Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF. The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol. 2016 Feb; 195(2):321-9. PMID: 26343985.
      View in: PubMed
    42. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb; 195(2):313-20. PMID: 26327354.
      View in: PubMed
    43. Hussein AA, Cooperberg MR. Rebuttal to Drs. Markovina and Michalski. Brachytherapy. 2015 Nov-Dec; 14(6):761-2. PMID: 26254833.
      View in: PubMed
    44. Hussein AA, Cooperberg MR. Point: Surgery is the most cost-effective option for prostate cancer needing treatment. Brachytherapy. 2015 Nov-Dec; 14(6):753-5. PMID: 26249124.
      View in: PubMed
    45. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 7; 314(1):80-2. PMID: 26151271.
      View in: PubMed
    46. Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. BJU Int. 2016 Feb; 117(2):244-8. PMID: 26010160.
      View in: PubMed
    47. Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? BJU Int. 2016 Jun; 117(6):897-903. PMID: 26010251.
      View in: PubMed
    48. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K, Murphy DG, Penson DF, Miller DC. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol. 2016 Jun; 69(6):998-1012. PMID: 26056070.
      View in: PubMed
    49. Cooperberg MR. Editorial Comment. Urology. 2015 Jun; 85(6):1223. PMID: 26099866.
      View in: PubMed
    50. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Pratson CL, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Dec; 18(4):333-7. PMID: 26171882; PMCID: PMC4640947 [Available on 06/01/16].
    51. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20. PMID: 25600860.
      View in: PubMed
    52. Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol. 2016 May; 69(5):775-87. PMID: 26003223.
      View in: PubMed
    53. Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. Agent Orange and long-term outcomes after radical prostatectomy. Urol Oncol. 2015 Jul; 33(7):329.e1-6. PMID: 25998746.
      View in: PubMed
    54. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016 Jan; 117(1):102-9. PMID: 25238114.
      View in: PubMed
    55. Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44. PMID: 25913390.
      View in: PubMed
    56. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Jul; 22(7):658-62. PMID: 25872110.
      View in: PubMed
    57. Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May; 51(7):817-24. PMID: 25794605; PMCID: PMC4402138 [Available on 05/01/16].
    58. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Apr; 22(4):362-6. PMID: 25728968.
      View in: PubMed
    59. Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol. 2015 Sep; 68(3):480-6. PMID: 25656807.
      View in: PubMed
    60. Basto M, Cooperberg MR, Murphy DG. Proton therapy websites: information anarchy creates confusion. BJU Int. 2015 Feb; 115(2):183-5. PMID: 25756133.
      View in: PubMed
    61. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16. PMID: 25644324.
      View in: PubMed
    62. Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll PR, Cooperberg MR. Current Use of Imaging after Primary Treatment of Prostate Cancer. J Urol. 2015 Jul; 194(1):98-104. PMID: 25640648.
      View in: PubMed
    63. Nguyen HG, Welty CJ, Cooperberg MR. Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol. 2015 Jan; 25(1):65-70. PMID: 25405934.
      View in: PubMed
    64. Cooperberg MR. Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol. 2015 Jan 20; 33(3):238-40. PMID: 25512464.
      View in: PubMed
    65. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 2015 May 1; 121(9):1414-21. PMID: 25492369; PMCID: PMC4409453 [Available on 05/01/16].
    66. Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. J Urol. 2015 Apr; 193(4):1232-8. PMID: 25463986.
      View in: PubMed
    67. Ten Ham RM, Wilson LS, Broering JM, Cooperberg MR, Carroll P. Sustainable Measurement of Response Shift in Prostate Cancer Patients: Adjusting Health Related Quality of Life with the Then-Test. Value Health. 2014 Nov; 17(7):A651. PMID: 27202352.
      View in: PubMed
    68. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10. PMID: 25320374; PMCID: PMC4203422.
    69. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2349-56. PMID: 25304929; PMCID: PMC4221498.
    70. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11. PMID: 25261803.
      View in: PubMed
    71. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015 Oct; 68(4):600-8. PMID: 25242555.
      View in: PubMed
    72. Cooperberg MR. Progress in management of low-risk prostate cancer: how registries may change the world. Eur Urol. 2015 Jan; 67(1):51-2. PMID: 25242556.
      View in: PubMed
    73. Vickers AJ, Edwards K, Cooperberg MR, Mushlin AI. A simple schema for informed decision making about prostate cancer screening. Ann Intern Med. 2014 Sep 16; 161(6):441-2. PMID: 25222389; PMCID: PMC4412472.
    74. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. Eur Urol. 2015 Jun; 67(6):1019-25. PMID: 25174325; PMCID: PMC4412750 [Available on 06/01/16].
    75. Catto JW, Cooperberg MR, Cornu JN, Gratzke C, Novara G, Shariat SF, Vickers A. European urology: serving our readership through systematic peer review, use of reporting standards, and encouragement of postpublication review. Eur Urol. 2015 Feb; 67(2):188-90. PMID: 25175422.
      View in: PubMed
    76. Klein EA, Cooperberg MR, Carroll PR. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's letter to the editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60. Eur Urol. 2014 Dec; 66(6):e117-8. PMID: 25150174.
      View in: PubMed
    77. Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014 Nov 15; 120(22):3519-26. PMID: 25065910; PMCID: PMC4221407.
    78. Rouprêt M, Morgan TM, Bostrom PJ, Cooperberg MR, Kutikov A, Linton KD, Palou J, Martínez-Piñeiro L, van der Poel H, Wijburg C, Winterbottom A, Woo HH, Wirth MP, Catto JW. European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. Eur Urol. 2014 Oct; 66(4):628-32. PMID: 25043941.
      View in: PubMed
    79. Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2015 Feb; 67(2):326-33. PMID: 24998118; PMCID: PMC4282620 [Available on 02/01/16].
    80. Cooperberg MR. Implications of the new AUA guidelines on prostate cancer detection in the U.S. Curr Urol Rep. 2014 Jul; 15(7):420. PMID: 24844775.
      View in: PubMed
    81. Akaza H, Kim CS, Carroll P, Choi IY, Chung BH, Cooperberg MR, Hirao Y, Hinotsu S, Horie S, Lee JY, Namiki M, Ng CF, Onozawa M, Ozono S, Ueno S, Umbas R, Ye D, Zhu G. Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int. 2014; 2(2):50-69. PMID: 26153555; PMCID: PMC4099396.
    82. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597. PMID: 24893170; PMCID: PMC4043973.
    83. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8. PMID: 24274744.
      View in: PubMed
    84. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014 Sep; 66(3):550-60. PMID: 24836057.
      View in: PubMed
    85. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51. PMID: 24819235; PMCID: PMC4266691.
    86. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014 Nov; 114(5):661-6. PMID: 24588774; PMCID: PMC4153797.
    87. Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014 May; 24(3):288-92. PMID: 24614347.
      View in: PubMed
    88. Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur Urol. 2015 Mar; 67(3):451-7. PMID: 24746973.
      View in: PubMed
    89. Cooperberg MR. Prostate cancer: a new look at prostate cancer treatment complications. Nat Rev Clin Oncol. 2014 Jun; 11(6):304-5. PMID: 24687033.
      View in: PubMed
    90. Cooperberg MR. Editorial comment. J Urol. 2014 Jul; 192(1):80-1. PMID: 24703980.
      View in: PubMed
    91. Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer. 2014 Jun 1; 120(11):1656-62. PMID: 24647966.
      View in: PubMed
    92. Loeb S, Cooperberg MR. Early detection of prostate cancer. Urol Clin North Am. 2014 May; 41(2):xiii. PMID: 24725496.
      View in: PubMed
    93. Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):174-9. PMID: 24614692.
      View in: PubMed
    94. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014 Dec; 114(6b):E18-24. PMID: 24712895.
      View in: PubMed
    95. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer. 2014 Apr 15; 120(8):1263-71. PMID: 24510400.
      View in: PubMed
    96. Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int. 2014 Feb; 113(2):186-8. PMID: 24206066.
      View in: PubMed
    97. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol. 2014 Jun; 65(6):1023-31. PMID: 24491309.
      View in: PubMed
    98. Moreira DM, Cooperberg MR, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Kuchibhatla M, Freedland SJ. Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):91-6. PMID: 24418913; PMCID: PMC4564861.
    99. Jalloh M, Cooperberg MR. Implementation of PSA-based active surveillance in prostate cancer. Biomark Med. 2014; 8(5):747-53. PMID: 25123041.
      View in: PubMed
    100. Tseng YD, Paciorek AT, Martin NE, D'Amico AV, Cooperberg MR, Nguyen PL. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer. 2014 Mar 15; 120(6):824-32. PMID: 24301555.
      View in: PubMed
    101. Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol. 2013 Dec; 5(6):318-29. PMID: 24294290; PMCID: PMC3825107.
    102. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry. J Urol. 2014 Apr; 191(4):964-70. PMID: 24184370.
      View in: PubMed
    103. Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer. 2014 Feb 15; 120(4):507-12. PMID: 24496867.
      View in: PubMed
    104. Li X, Fang D, Cooperberg MR, Whitson JM, Lue TF, Zhou L, Shinohara K. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol. 2014 Aug; 32(4):1061-6. PMID: 24141807.
      View in: PubMed
    105. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014 Jan 15; 120(2):197-204. PMID: 24127391; PMCID: PMC4149056.
    106. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):391-7. PMID: 24100644; PMCID: PMC3830588.
    107. Cooperberg MR, Cowan JE, Carroll PR. Reply to A. Azad et al. J Clin Oncol. 2013 Sep 10; 31(26):3296-7. PMID: 23943835.
      View in: PubMed
    108. Cooperberg MR. Re-examining racial disparities in prostate cancer outcomes. J Clin Oncol. 2013 Aug 20; 31(24):2979-80. PMID: 23878300.
      View in: PubMed
    109. Glass AS, Punnen S, Cooperberg MR. Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol. 2013 Jul; 54(7):417-25. PMID: 23878682; PMCID: PMC3715703.
    110. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013 Jul; 112(2):E67-75. PMID: 23795800.
      View in: PubMed
    111. Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013 Jul; 23(4):331-6. PMID: 23619582.
      View in: PubMed
    112. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013 Jul; 2(4):445-60. PMID: 24236685.
      View in: PubMed
    113. Cooperberg MR. Expanding utilization of intensity-modulated radiotherapy for prostate cancer: soaring costs, dubious benefits: comment on "Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy". JAMA Intern Med. 2013 Jun 24; 173(12):1143-4. PMID: 23689487.
      View in: PubMed
    114. Cooperberg MR. Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening. Eur Urol. 2013 Jun; 63(6):1130. PMID: 23608080.
      View in: PubMed
    115. Glass AS, Cary KC, Cooperberg MR. Risk-based prostate cancer screening: who and how? Curr Urol Rep. 2013 Jun; 14(3):192-8. PMID: 23532499.
      View in: PubMed
    116. Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll P. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol. 2013 Jul; 43(7):756-66. PMID: 23723314.
      View in: PubMed
    117. Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll PR, Kenfield SA, Greene KL. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013 Jul; 82(1):60-5. PMID: 23706257.
      View in: PubMed
    118. Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013 Dec; 64(6):905-15. PMID: 23721958.
      View in: PubMed
    119. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7. PMID: 23587869.
      View in: PubMed
    120. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care. 2013 Apr; 51(4):295-300. PMID: 23269114; PMCID: PMC3604989.
    121. Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013 Aug; 112(4):E314-20. PMID: 23451984.
      View in: PubMed
    122. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10; 31(11):1428-34. PMID: 23460710.
      View in: PubMed
    123. Blaschko SD, Weiss DA, Odisho AY, Greene KL, Cooperberg MR. Proximal bulbar periurethral abscess. Int Braz J Urol. 2013 Jan-Feb; 39(1):137-8. PMID: 23489506.
      View in: PubMed
    124. Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013 Mar; 111(3):437-50. PMID: 23279038; PMCID: PMC3587031.
    125. Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):202-6. PMID: 23271774; PMCID: PMC3540869.
    126. Cooperberg MR. Factors associated with treatment received by men diagnosed with prostate cancer in queensland, australia. BJU Int. 2012 Dec; 110(11 Pt B):E720. PMID: 23017189.
      View in: PubMed
    127. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 1; 18(19):5471-8. PMID: 23008476; PMCID: PMC3604990.
    128. Porten SP, Cooperberg MR. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012 Sep; 22(5):385-9. PMID: 22842681.
      View in: PubMed
    129. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019. Eur Urol. 2012 Nov; 62(5):e88. PMID: 22921716.
      View in: PubMed
    130. Murphy DG, Williams S, Cooperberg MR. Prostate cancer: new types of radiotherapy improve cancer outcome but at what cost? Nat Rev Urol. 2012 Aug; 9(8):415-7. PMID: 22750953.
      View in: PubMed
    131. Glass AS, Cooperberg MR, Carroll PR. Early detection of prostate cancer: more information, more clarity. Eur Urol. 2012 Nov; 62(5):753-5; discussion 755-6. PMID: 22766168.
      View in: PubMed
    132. Cooperberg MR, Chan JM. Editorial comment. Urology. 2012 Aug; 80(2):305-6. PMID: 22749427.
      View in: PubMed
    133. Cooperberg MR. Will biomarkers save prostate cancer screening? Eur Urol. 2012 Dec; 62(6):962-3; discussion 964-5. PMID: 22749734.
      View in: PubMed
    134. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis. 2012 Dec; 15(4):374-9. PMID: 22710832; PMCID: PMC3815610.
    135. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83. PMID: 22698574.
      View in: PubMed
    136. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. Cancer. 2012 Dec 15; 118(24):6046-54. PMID: 22674220.
      View in: PubMed
    137. Cooperberg MR. Urological cancer: For localized prostate cancer, does technology equal progress? Nat Rev Clin Oncol. 2012 Jul; 9(7):371-2. PMID: 22665365.
      View in: PubMed
    138. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol. 2013 May; 63(5):936-40. PMID: 22521093; PMCID: PMC3443544.
    139. Cooperberg MR. To predict the future, consider the present as well as the past. Eur Urol. 2012 Jul; 62(1):53-4. PMID: 22521092.
      View in: PubMed
    140. Cooperberg MR. Thwarting high-risk prostate cancer: the right treatments for the right patients. Eur Urol. 2012 Jun; 61(6):1107-9. PMID: 22475772.
      View in: PubMed
    141. Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3. PMID: 22332166.
      View in: PubMed
    142. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol. 2012 Mar; 42(3):226-36. PMID: 22217576.
      View in: PubMed
    143. Cooperberg MR, Odisho AY, Carroll PR. Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol. 2012 Feb 10; 30(5):476-8. PMID: 22215744.
      View in: PubMed
    144. Cooperberg MR. Adverse effects of androgen deprivation and the limits of national tumor registries. Eur Urol. 2012 Apr; 61(4):701-3; discussion 703-4. PMID: 22176779.
      View in: PubMed
    145. Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):189-94. PMID: 22343837.
      View in: PubMed
    146. Cooperberg MR. High-risk prostate cancer: treat the prostate. Lancet. 2011 Dec 17; 378(9809):2056-7. PMID: 22056154.
      View in: PubMed
    147. Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):100-5. PMID: 22042252.
      View in: PubMed
    148. Cooperberg MR. External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence. Asian J Androl. 2012 Jan; 14(1):132-3. PMID: 22036804; PMCID: PMC3752845.
    149. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int. 2012 May; 109(10):1520-4. PMID: 21999368; PMCID: PMC3288727.
    150. Cooperberg MR. Words of wisdom. Re: Radical prostatectomy versus watchful waiting in early prostate cancer. Eur Urol. 2011 Oct; 60(4):868-9. PMID: 21878196.
      View in: PubMed
    151. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14. PMID: 21934053; PMCID: PMC3831607.
    152. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10; 29(26):3510-6. PMID: 21844498; PMCID: PMC3179251.
    153. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27):3669-76. PMID: 21825257.
      View in: PubMed
    154. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9. PMID: 21679982.
      View in: PubMed
    155. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011 Nov 15; 117(22):5039-46. PMID: 21647869; PMCID: PMC3170662.
    156. Cooperberg MR. Editorial comment. Urology. 2011 Jun; 77(6):1336-7. PMID: 21624594.
      View in: PubMed
    157. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800. PMID: 21632511.
      View in: PubMed
    158. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7. PMID: 21478037.
      View in: PubMed
    159. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60. PMID: 21419438.
      View in: PubMed
    160. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011 Oct 1; 117(19):4406-13. PMID: 21412760.
      View in: PubMed
    161. Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71. PMID: 21347810; PMCID: PMC3099175.
    162. Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol. 2011 Feb 1; 29(4):345-7. PMID: 21189396.
      View in: PubMed
    163. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011 Jan 10; 29(2):235-41. PMID: 21135285; PMCID: PMC3058279.
    164. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34. PMID: 21115873; PMCID: PMC3058278.
    165. Reese AC, Sadetsky N, Carroll PR, Cooperberg MR. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer. 2011 Jan 15; 117(2):283-9. PMID: 21210472.
      View in: PubMed
    166. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010 Nov 15; 116(22):5226-34. PMID: 20690197; PMCID: PMC2975879.
    167. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6. PMID: 20846693.
      View in: PubMed
    168. Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012 Mar-Apr; 30(2):155-60. PMID: 20800514.
      View in: PubMed
    169. Eisner BH, Zargooshi J, Berger AD, Cooperberg MR, Doyle SM, Sheth S, Stoller ML. Gender differences in subcutaneous and perirenal fat distribution. Surg Radiol Anat. 2010 Nov; 32(9):879-82. PMID: 20607260.
      View in: PubMed
    170. Castle SM, Cooperberg MR, Sadetsky N, Eisner BH, Stoller ML. Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis. J Urol. 2010 Aug; 184(2):579-83. PMID: 20639021.
      View in: PubMed
    171. Vickers AJ, Salz T, Basch E, Cooperberg MR, Carroll PR, Tighe F, Eastham J, Rosen RC. Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak. 2010; 10:34. PMID: 20565745; PMCID: PMC2893444.
    172. Cooperberg MR. Specialist visits (urologist, radiation oncologist, medical oncologist) are strongly associated with treatment received for prostate cancer in the USA. Evid Based Med. 2010 Jun; 15(3):95-6. PMID: 20522696.
      View in: PubMed
    173. Reese AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010 Jul; 184(1):114-9. PMID: 20478578.
      View in: PubMed
    174. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologist density and county-level urologic cancer mortality. J Clin Oncol. 2010 May 20; 28(15):2499-504. PMID: 20406931; PMCID: PMC2881728.
    175. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010 Oct; 106(7):1022-9. PMID: 20184571.
      View in: PubMed
    176. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010 Mar 1; 28(7):1117-23. PMID: 20124165; PMCID: PMC2834465.
    177. Seo Y, Aparici CM, Cooperberg MR, Konety BR, Hawkins RA. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J Nucl Med. 2010 Jan; 51(1):31-6. PMID: 20008977; PMCID: PMC2821016.
    178. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5. PMID: 19681901; PMCID: PMC2821458.
    179. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009 Sep 10; 27(26):4306-13. PMID: 19667269; PMCID: PMC2744272.
    180. Cooperberg MR, Hinotsu S, Chancellor MB, Homma Y, Nelson PS, Matsuyama H, Menon M, Kucuk O, Hara I, Egawa S, Uzzo RG, Kanayama HO, Okuyama A, Akaza H. Fourth joint meeting of the American Urological Association and the Japanese Urological Association Specialty Society program at the 104th annual meeting of the American Urological Association at Chicago 2009. Int J Urol. 2009 Aug; 16(8):703-8. PMID: 19682110.
      View in: PubMed
    181. Cooperberg MR, Carroll PR. Prostate-cancer screening. N Engl J Med. 2009 Jul 9; 361(2):203; author reply 204-5. PMID: 19593852.
      View in: PubMed
    182. Cooperberg MR, Birkmeyer JD, Litwin MS. Defining high quality health care. Urol Oncol. 2009 Jul-Aug; 27(4):411-6. PMID: 19573771.
      View in: PubMed
    183. Cooperberg MR, Porter MP, Konety BR. Candidate quality of care indicators for localized bladder cancer. Urol Oncol. 2009 Jul-Aug; 27(4):435-42. PMID: 19573775.
      View in: PubMed
    184. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Jan; 105(1):88-92. PMID: 19549119.
      View in: PubMed
    185. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16; 101(12):878-87. PMID: 19509351; PMCID: PMC2697208.
    186. Cooperberg MR, Konety BR. Management of localized prostate cancer in men over 65 years. Curr Opin Urol. 2009 May; 19(3):309-14. PMID: 19357512.
      View in: PubMed
    187. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010 Apr; 57(4):622-9. PMID: 19375843; PMCID: PMC2930030.
    188. Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh QY, Stoller ML. Patients with primary hyperparathyroidism--why do some form stones? J Urol. 2009 May; 181(5):2141-5. PMID: 19296981.
      View in: PubMed
    189. Konety BR, Cooperberg MR, Carroll PR. Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med. 2009 Feb 3; 150(3):220-1; author reply 221-2. PMID: 19189916.
      View in: PubMed
    190. Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. Geographic distribution of urologists throughout the United States using a county level approach. J Urol. 2009 Feb; 181(2):760-5; discussion 765-6. PMID: 19091334.
      View in: PubMed
    191. Cooperberg MR. Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer. 2008 Dec 1; 113(11):3062-6. PMID: 18855919; PMCID: PMC2948568.
    192. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008 Dec; 180(6):2415-22; discussion 2422. PMID: 18930279.
      View in: PubMed
    193. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008 Jul 1; 113(1):78-83. PMID: 18491376.
      View in: PubMed
    194. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. PMID: 18433013.
      View in: PubMed
    195. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008 Jun; 179(6):2131-5. PMID: 18423754.
      View in: PubMed
    196. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9. PMID: 18306379.
      View in: PubMed
    197. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun; 26(3):211-8. PMID: 18369637; PMCID: PMC2948572.
    198. Cooperberg MR, Duh QY, Stackhouse GB, Stoller ML. Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidism. Int J Urol. 2007 Dec; 14(12):1113-5. PMID: 18036056.
      View in: PubMed
    199. Whitson JM, Cooperberg MR, Stackhouse GB, Stoller ML. Urinary citrate levels do not correlate with urinary pH in patients with urinary stone formation. Urology. 2007 Oct; 70(4):634-7. PMID: 17991528.
      View in: PubMed
    200. Cooperberg MR, McAninch JW, Alsikafi NF, Elliott SP. Urethral reconstruction for traumatic posterior urethral disruption: outcomes of a 25-year experience. J Urol. 2007 Nov; 178(5):2006-10; discussion 2010. PMID: 17869302.
      View in: PubMed
    201. Cooperberg MR, Modak S, Konety BR. Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. J Urol. 2007 Nov; 178(5):2103-8; discussion 2108. PMID: 17870128.
      View in: PubMed
    202. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007 Sep; 178(3 Pt 2):S14-9. PMID: 17644125; PMCID: PMC2987559.
    203. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91. PMID: 17039503.
      View in: PubMed
    204. Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll PR. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006 Feb 15; 106(4):789-95. PMID: 16400651.
      View in: PubMed
    205. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10; 23(32):8146-51. PMID: 16278465.
      View in: PubMed
    206. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov; 66(5 Suppl):76-82. PMID: 16194711.
      View in: PubMed
    207. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005 Nov; 66(5):1060-5. PMID: 16286124.
      View in: PubMed
    208. Cooperberg MR, Chi T, Jad A, Cha I, Turek PJ. Variability in testis biopsy interpretation: implications for male infertility care in the era of intracytoplasmic sperm injection. Fertil Steril. 2005 Sep; 84(3):672-7. PMID: 16169401.
      View in: PubMed
    209. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun; 173(6):1938-42. PMID: 15879786; PMCID: PMC2948569.
    210. Camargo AH, Cooperberg MR, Ershoff BD, Rubenstein JN, Meng MV, Stoller ML. Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literature. Urology. 2005 May; 65(5):882-7. PMID: 15882716.
      View in: PubMed
    211. Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll PR, Kane CJ. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol. 2005 Apr; 173(4):1132-8. PMID: 15758721.
      View in: PubMed
    212. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005 Apr; 173(4):1126-31. PMID: 15758720.
      View in: PubMed
    213. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005 Mar; 173(3):732-6. PMID: 15711258.
      View in: PubMed
    214. Cooperberg MR, Stoller ML. Percutaneous neuromodulation. Urol Clin North Am. 2005 Feb; 32(1):71-8, vii. PMID: 15698879.
      View in: PubMed
    215. Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004 Sep; 18(10):1239-47; discussion 1248-50, 1256-8. PMID: 15526829.
      View in: PubMed
    216. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 1; 22(11):2141-9. PMID: 15169800; PMCID: PMC2997214.
    217. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll PR. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004 Jun; 171(6 Pt 1):2255-9. PMID: 15126797.
      View in: PubMed
    218. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep. 2004 Jun; 5(3):166-72. PMID: 15161564.
      View in: PubMed
    219. Cooperberg MR, Downs TM, Carroll PR. Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery. 2004 Apr; 135(4):452-3; discussion 454. PMID: 15041971.
      View in: PubMed
    220. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004 Apr; 171(4):1393-401. PMID: 15017184.
      View in: PubMed
    221. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10. PMID: 14744788.
      View in: PubMed
    222. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003 Dec; 170(6 Pt 2):S21-5; discussion S26-7. PMID: 14610406.
      View in: PubMed
    223. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38. PMID: 14765015.
      View in: PubMed
    224. Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003 Nov; 170(5):1804-7. PMID: 14532780.
      View in: PubMed
    225. Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003 Sep; 170(3):905-8. PMID: 12913727.
      View in: PubMed
    226. Cooperberg MR, Master VA, Carroll PR. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. J Urol. 2003 Aug; 170(2 Pt 1):512-5. PMID: 12853811.
      View in: PubMed
    227. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003 Jul 2; 95(13):981-9. PMID: 12837834; PMCID: PMC2994265.
    228. Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS, Carroll PR. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology. 2003 Jan; 61(1):190-6. PMID: 12559294.
      View in: PubMed
    229. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002 Aug; 168(2):491-5. PMID: 12131295.
      View in: PubMed
    230. Goldstein LJ, Davies RR, Rizzo JA, Davila JJ, Cooperberg MR, Shaw RK, Kopf GS, Elefteriades JA. Stroke in surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac Cardiovasc Surg. 2001 Nov; 122(5):935-45. PMID: 11689799.
      View in: PubMed
    231. Cooperberg MR, Fiedler PN. Ki-1 anaplastic large-cell lymphoma occurring at the site of ileocolonic anastomosis in a patient treated surgically for colonic adenocarcinoma: case report and review of the literature. Ann Diagn Pathol. 2001 Jun; 5(3):162-7. PMID: 11436170.
      View in: PubMed
    232. Cooperberg MR, Chambers SK, Rutherford TJ, Foster HE. Cystic pelvic pathology presenting as falsely elevated post-void residual urine measured by portable ultrasound bladder scanning: report of 3 cases and review of the literature. Urology. 2000 Apr; 55(4):590. PMID: 10754180.
      View in: PubMed
    233. Shrimdkandada S, Fu SQ, Yin LH, Guo XY, Nanakorn T, Peng XY, Dizon D, Lin D, Cooperberg M, Won JH, Deisseroth A. Methods for Chemoprotection and Chemosensitization : MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors to Modify Epithelian Neoplastic Cells. Methods Mol Med. 2000; 35:609-16. PMID: 21390834.
      View in: PubMed
    234. Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood. 1998 Jul 15; 92(2):672-82. PMID: 9657770.
      View in: PubMed
    Matthew's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP